# Medicinrådet (Danish Medicines Council)

Source: https://onco.cc/institutions/medicinraadet/  
OnCo record `medicinraadet` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The council set up by Denmark's five regions in 2017 to recommend which new hospital medicines, including cancer medicines, become standard treatment; its recommendations are not binding on the regions. It weighs benefit against the price Amgros negotiates, can accept a higher cost for very severe disease, and can recommend a drug under a risk-sharing deal.

## Summary

Medicinrådet was established on 1 January 2017 by the board of Danske Regioner, replacing two earlier regional councils, RADS (from 2009) and KRIS (from 2012). Its terms of reference say it recommends to the five regions whether new medicines and new indications should be taken into use, on the basis of price negotiations and tenders by Amgros, that its recommendations are not binding on the regions, and that its decisions cannot be appealed to another administrative authority. The Council has up to 18 members, including a member from each region, representatives of the medical societies and two patient representatives, with observers from the pharmaceutical industry association, Sundhedsstyrelsen, the Danish Medicines Agency and Amgros; more than 50 expert committees with more than 500 members prepare its assessments. Its address is Dampfærgevej 21-23, Copenhagen; the coordinates are an approximate street point.

It works to seven principles for prioritising hospital medicines that the parties in the Folketing agreed in March 2016, among them that a medicine with well-documented added effect should not be rejected on cost alone and that there must be a reasonable relation between its price and its added value. Since its founding it has had a mandate to weigh severity: in particular cases it may accept higher costs, or recommend a medicine on weaker evidence than it normally requires, for example for disease with unusually early death or where the medicine is the only real curative treatment. In 2025 it received 81 applications from companies, against 66 in 2024. In October 2026 it recommended trastuzumab deruxtecan, under a risk-sharing agreement, for HER2-positive cancer of the stomach and gastro-oesophageal junction and for a group of people with lung cancer carrying a particular genetic change, and did not recommend sacituzumab govitecan for a group of previously treated breast cancer patients because it judged the cost not acceptable for the effect.

## Fields

- Kind: Institution
- Last checked: 2026-11-11
- Also known as: Danish Medicines Council; Medicinraadet
- City: Copenhagen, DK
- Type: government
- Website: https://medicinraadet.dk

## Sources

- Medicinrådet: om os: https://medicinraadet.dk/om-os
- Medicinrådet: in English: https://medicinraadet.dk/om-os/in-english
- Kommissorium for Medicinrådet, version 1.7 (PDF): https://filer.medicinraadet.dk/media/nvmdgxqu/medicinradet-kommissorium-version-1-7.pdf
- Princippapir om prioritering for sygehuslægemidler, 31 March 2016 (PDF): https://filer.medicinraadet.dk/media/1oxfmhsz/ad-pkt-4-folketingets-7-principper-for-prioritering-af-sygehuslaegemidler_final-a.pdf
- Medicinrådets anvendelse af alvorlighedsprincippet (PDF): https://filer.medicinraadet.dk/media/weanjjre/medicinr%C3%A5dets-anvendelse-af-alvorlighedsprincippet-januar-2021.pdf
- Medicinrådet: decisions in October 2026: https://medicinraadet.dk/nyheder/2026/overblik-medicinradets-beslutninger-i-oktober-2026

## Connected records

- drugs: [Brexucabtagene autoleucel](https://onco.cc/drugs/brexucabtagene-autoleucel/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/), [Mogamulizumab](https://onco.cc/drugs/mogamulizumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Teclistamab](https://onco.cc/drugs/teclistamab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- institutions: [Lægemiddelstyrelsen (Danish Medicines Agency)](https://onco.cc/institutions/danish-medicines-agency/), [Sundhedsstyrelsen (Danish Health Authority)](https://onco.cc/institutions/sundhedsstyrelsen/)
- terms: [Health technology assessment (HTA), reimbursement and QALYs](https://onco.cc/terms/hta/)
- people: [Birgitte Klindt Poulsen](https://onco.cc/people/birgitte-klindt-poulsen/), [Søren Gaard](https://onco.cc/people/soren-gaard/)

---
JSON: https://onco.cc/api/v1/entities/medicinraadet.json